Cortactin overexpression was significantly associated with higher TNM stage (P=0.005), as 38 out of the 77 cortactin-overexpressing tumours (49%) were stage IV, as compared with 50 out of the total 176 tumours analysed (28%). Here, CTTN is linked to neoplasm.